Limits...
Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.

Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, National Birth Defects Prevention Stu - BMJ (2015)

Bottom Line: Citalopram, escitalopram, fluoxetine, paroxetine, or sertraline use in the month before through the third month of pregnancy.Sertraline was the most commonly reported SSRI, but none of the five previously reported birth defects associations with sertraline was confirmed.For nine previously reported associations between maternal SSRI use and birth defect in infants, findings were consistent with no association.

View Article: PubMed Central - PubMed

Affiliation: National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA NZR5@cdc.gov.

Show MeSH

Related in: MedlinePlus

Flow chart of participants through study
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496787&req=5

fig1: Flow chart of participants through study

Mentions: A total of 38 009 women with births between 1997 and 2009 were interviewed for the NBDPS. We excluded women reporting pre-existing diabetes (n=719), known use of teratogenic drugs (n=65), or depression, anxiety, bipolar disorder, or obsessive compulsive disorder but not reporting any antidepressant use (n=30). And, after excluding defects with no previous reported associations with SSRIs, the final analyses included 17 293 unexposed cases, 659 cases exposed to citalopram, escitalopram, fluoxetine, paroxetine or sertraline, 9559 unexposed controls, and 298 controls that were exposed to one of these SSRIs (figure).


Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.

Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, National Birth Defects Prevention Stu - BMJ (2015)

Flow chart of participants through study
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496787&req=5

fig1: Flow chart of participants through study
Mentions: A total of 38 009 women with births between 1997 and 2009 were interviewed for the NBDPS. We excluded women reporting pre-existing diabetes (n=719), known use of teratogenic drugs (n=65), or depression, anxiety, bipolar disorder, or obsessive compulsive disorder but not reporting any antidepressant use (n=30). And, after excluding defects with no previous reported associations with SSRIs, the final analyses included 17 293 unexposed cases, 659 cases exposed to citalopram, escitalopram, fluoxetine, paroxetine or sertraline, 9559 unexposed controls, and 298 controls that were exposed to one of these SSRIs (figure).

Bottom Line: Citalopram, escitalopram, fluoxetine, paroxetine, or sertraline use in the month before through the third month of pregnancy.Sertraline was the most commonly reported SSRI, but none of the five previously reported birth defects associations with sertraline was confirmed.For nine previously reported associations between maternal SSRI use and birth defect in infants, findings were consistent with no association.

View Article: PubMed Central - PubMed

Affiliation: National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA NZR5@cdc.gov.

Show MeSH
Related in: MedlinePlus